Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1671 1672
This examiner grants 100% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18035809 | ENGINEERED PROTEIN FOR RAPID, EFFICIENT CAPTURE OF PATHOGEN-SPECIFIC ANTIBODIES | Non-Final OA | Massachusetts Institute of Technology |
| 18550730 | METHODS AND COMPOSITIONS FOR MATURE DENGUE VIRUSES AS VACCINES AND DIAGNOSTICS | Non-Final OA | The University of North Carolina at Chapel Hill |
| 18330475 | TETRAVALENT DENGUE INACTIVATED VACCINE | Non-Final OA | ARMY MEDICAL UNIVERSITY |
| 18448721 | DOSING AND SCHEDULING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES | Non-Final OA | Gilead Sciences, Inc. |
| 18271901 | REPLICATION-COMPETENT ADENOVIRUS TYPE 4 SARS-COV-2 VACCINES AND THEIR USE | Non-Final OA | The U.S.A., as Represented by The Secretary, Department of Health and Human Services |
| 18271640 | NANOWIRE-BASED IMMUNOFLUORESCENCE KIT FOR DETECTING SARS CORONAVIRUS 2 ANTIBODY, AND USE THEREOF | Non-Final OA | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY |
| 18283516 | IMMUNOGENIC COMPOSITIONS | Non-Final OA | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC |
| 18550895 | CANCER VACCINE AND METHOD OF USE THEREOF | Non-Final OA | United States Department of Health and Human Services and the National Institute of Health |
| 18466675 | MICROBIOME IDENTIFICATION AND BACTERIOPHAGE FORMULATIONS | Non-Final OA | Parallel Health, Inc. |
| 18549941 | VACCINE COMPOSITION COMPRISING A LEISHMANIA HOST CELL EXPRESSING AT LEAST ONE PROTEIN OF THE FAMILY CORONAVIRIDAE | Non-Final OA | Vismederi S.R.L. (10%) |
| 18278647 | PEPTIDES AND THEIR USE IN DIAGNOSIS OF SARS-COV-2 INFECTION | Non-Final OA | Vivocens AB |
| 18366915 | VACCINES FOR THE TREATMENT AND PREVENTION OF SEASONAL AND EMERGING INFECTIONS | Non-Final OA | Longhorn Vaccines and Diagnostics, LLC |
| 18347891 | COMPOSITIONS AND METHODS FOR RECOMBINANT PARVOVIRUS PRODUCTION | Final Rejection | AAVNERGENE INC. |
| 18270917 | FULLY HUMAN BROAD-SPECTRUM NEUTRALIZING ANTIBODY 76E1 AGAINST CORONAVIRUS, AND USE THEREOF | Non-Final OA | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES |
| 18270390 | Method of Obtaining Betulin as an Adjuvant in a Vaccine Against Coronavirus SARS-COV-2 | Non-Final OA | BETUVAKS LIMITED LIABILITY COMPANY |
| 18344693 | CONTROL FOR PROTEIN-BASED ASSAY | Non-Final OA | ZeptoMetrix LLC |
| 18256484 | METHODS OF PRODUCING ADENOVIRUS | Non-Final OA | ASTRAZENECA UK LIMITED |
| 18248166 | METHOD FOR DETERMINING WHETHER OR NOT VIRUS-NEUTRALIZING ANTIBODIES ARE PRESENT AND IN VITRO METHOD FOR SCREENING COMPOUNDS FOR THEIR ABILITY TO NEUTRALIZE A VIRUS | Non-Final OA | EXIMMIUM BIOTECHNOLOGIES GMBH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy